Targeted treatments for complex, chronic heart diseases in cats and dogs
Next generation veterinary pain management for daily use
The world’s first veterinary registered PPI for canine gastric ulceration
Diagnostics for Gastric markers that indicate health and wellness
Tackling some of the most debilitating and chronic diseases of aging in companion animals
Targeted treatments for complex, chronic heart diseases in cats and dogs
US product launch Q4 2023
EU launch Q1 2024
Next generation veterinary pain management for daily use
US product launch Q1 2024;
Q2 2024
The world’s first veterinary registered PPI for canine gastric ulceration
US product launch Q1 2023
EU launch Q3 2023
Diagnostics for Gastric markers that indicate health and wellness
US/EU product launch Q2 2023
Tackling some of the most debilitating and chronic diseases of aging in companion animals
Our research and development model is simple but effective.
We identify diseases in companion animals where there are no approved treatments.
We formulate novel solutions with species specific doses and presentations.
Our research team are bridging the gap between bench and bedside by conducting clinical trials that benefit client-owned dogs and cats.
The data collected is then used as clinical data for veterinary patients
We prove the safety and efficacy of our products to FDA and EMA requirements.
Our research and development model is simple but effective.
We identify diseases in companion animals where there are no approved treatments.
We formulate novel solutions with species specific doses and presentations.
Our translational research team are bridging the gap between bench and bedside by conducting clinical trials that benefit client-owned dogs and cats.
The data collected is then used both as clinical data for veterinary patients and preclinical data for human patients.
We prove the safety and efficacy of our products to FDA and EMA requirements.
We harness our extensive animal research to identify synergies in human medicine.
Keep up to date with our latest advancements and news as we continue to develop and commercialise medicines and diagnostics for use in companion animals.
TriviumVet are proud to announce the publication of the results of the RapaCat Study in the Journal of the American Veterinary Medical Association. This study used our proprietary veterinary mTOR inhibitor Felycin™ to target early Hypertrophic Cardiomyopathy (HCM) and was tested in stage B1 and B2 client-owned cats with the disease. Felycin™ prevented progression of hypertrophy.
Catch up on all the latest news from TriviumVet and their range of candidates targeting cardiology, pain, gastroenterology, age-related diseases and general wellness.
At TriviumVet we are delighted to work with some of the veterinary industry's most passionate, knowledgeable and renowned thought leaders. We started working with Dr. Olby on the CHASE Questionnaire study to assess a novel pain management product in dogs. This award is an incredible recognition of her research career and achievements. Well done Dr. Olby!